Yang and colleagues found that treating genetically modified CD8+ T cells using anti-tumor T cell receptors (TCR) with different combinations of interleukins (IL-12 plus IL-7 or IL-21) is capable of re-programming the late effector cells from TILs isolated from patients with melanoma [53]. The gene discussed is CD8A; the disease is neoplasm.